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The aim of this study was to investigate the effects of oral magnesium treatment on clinical findings
such as number of sensitive points, severity of pain and functional capacity in primary Fibromyalgia syndrome
patients.
Twenty-five primary fibromyalgia syndrome patients (24 female, 1 male) were enrolled
to the study. Patients were examined in terms of pain in rest and activity, number of sensitive points and functional
capacity. Fibromyalgia Impact Questionnaire and Visual Analogue Scale (VAS) were used for functional
assessment and pain respectively. Serum and twenty-four hour urine magnesium levels were measured. The
serum and urine magnesium levels were measured by original kits of Abbott Aeroset autoanaylzer (Abbott
Laboratories, Abbott Park, IL, 60064, USA). Patients were administered magnesium citrate (Magnesium
Diasporal 600 mg sachets b.i.d. orally) therapy for two months. At the end of two months, patients were re-
examined in terms of recorded clinical and laboratory findings.
The mean age of patients was 44.8 (SD=7.4) years and the mean duration of disease was 25.4 (SD=19.2)
months. There was a significant improvement in number of sensitive points, pain and Fibromyalgia Impact
Questionnaire score at the end of two-month therapy (p<0.001). In the end of the treatment period, the levels of
the serum and 24-hour urine magnesium levels remained within normal ranges and the changes could not reach
statistically significance (p>0.05).
In the treatment of Fibromyalgia syndrome, magnesium citrate therapy was found to be safe and
efficient on number of sensitive points, pain and functional state.
Fibromyalgia syndrome, magnesium, trace element, clinical findings
Bu çalışmanın amacı, primer fibromiyalji sendromu olan hastalarda oral magnezyum tedavisinin hassas
nokta sayısı, ağı şiddeti gibi klinik bulgular ve fonksiyonel kapasite üzerine olan etkilerini araştırmaktır.
Yirmi-beş primer fibromiyalji sendromu olan hasta (24 bayan 1 erkek) çalışmaya
dahil edildi. Hastalar istirahat ve aktivite ağrıları, hassas nokta sayısı ve fonksiyonel kapasite açısından
değerlendirildi. Fibromiyalji etkinlik sorgulaması ve vizuel analog skala (VAS), sırasıyla fonksiyonel durum ve
ağrı şiddetini değerlendirmek için kullanıldı. Serum ve 24 saatlik idrarda magnezyum seviyesi ölçüldü. Serum ve
idrar magnezyum düzeyleri Abbott Aeroset autoanaylzer orjinal kiti (Abbott Laboratories, Abbott Park, IL,
60064, USA) ile ölçüldü. Hastalar iki ay boyunca magnezyum sitrat (Magnesium Diasporal 600 mg saşe b.i.d.
oral) tedavisi aldılar. İki ayın sonunda, tekrar muayene edilip klinik bulgularıkaydedildi.
Hastaların yaş ortalaması 44.8 (SS=7.4) yıl ve hastalık süresi ortalama 25.4 (SS=19.2) aydı.
Hassas nokta sayısı, ağrı ve fibromiyalji etkinlik sorgulaması skorunda tedavi öncesine göre ikinci ayın sonunda
anlamlı iyileşme olduğu gözlendi (p<0.001). Tedavi periyodunun sonunda, serum ve 24 saatlik idrardaki
magnezyum düzeyleri normal sınırlar içinde kaldı ve değişiklikler istatistiksel olarak anlamlı düzeye ulaşamadı
(p>0.05).
Fibromiyalji sendromunun tedavisinde magnezyum sitrat tedavisi hassas nokta sayısı, ağrı ve
fonksiyonel durum üzerinde etkili ve güvenli olarak bulundu.
magnezyum, eser element, klinik bulgularFibromiyalji sendromu,
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Fibromyalgia syndrome (FMs) is a chronic pain
syndrome characterized by disseminated pain and
stiffness, multiple tender points, and fatigue. This
pain syndrome has an incidence of 2% in the general
population and occurs with higher frequency among
women in middle age. FMs is categorized as primary
or secondary. In primary fibromyalgia the causes are
not known, and in secondary fibromyalgia the causes
such as trauma, cancer, thyroid diseases and
pathologies of rheumatic and connective tissues can
be identified. Primary fibromyalgia is the more
common form. Since the etiology of FMs is not
clarified exactly, the treatment is generally
symptomatic. Recently, the treatment of FMs is
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Primary Fibromyalgia Syndrome
focused on the mechanisms such as sleep disorders,
neurochemical differentiations, abnormal pain
perception and muscle hypo perfusion due to regional
vasomotor dysregulation. It is considered that
decrease in blood flow beneath the sensitive points,
decrease in ATP and local hypoxia is of importance in
the development of symptoms in FMs. Magnesium is
a trace element which plays a considerable role in ATP
synthesis and extremely important for adequate
muscle metabolism and function together with
calcium. There are several reports suggesting the
magnesium level of the patients with FMs is below the
normal range. It was reported that magnesium
therapy, combined with malic acid, was effective in
improving the pain and number of sensitive points in
patients with FMs. However, clinical efficacy of
magnesium therapy alone in FMs patients has not been
investigated sufficiently.
The aim of this study was to investigate the
effects of oral magnesium treatment on clinical
findings such as number of sensitive points, level of
pain and functional capacity as well as laboratory
findings such as serum and urine level of magnesium
in patients with primary Fms.
After receiving approval of the local ethics
committee and informed consent of the patients, 25
patients (24 women and one man) who had a FMs
diagnosis according to 1990 criteria of American
College of Rheumatism (ACR) were recruited to the
study. The demographic features, disease durations
and accompanying symptoms (arthralgia, myalgia,
anxiety, forgetfulness, sleep problems and fatigue) of
the patients were documented. Visual analogue scale
(VAS; 10 cm) was used for the evaluation of the day
and night pain of the patients. The sensitive points
defined by ACR were determined by applying a 4 kg
pressure by thumb on the specific points of body and
the number of sensitive points on whole body was
recorded.
The Fibromyalgia Impact Questionnaire (FIQ)
adjusted for the Turkish population was used for the
functional evaluation of the patients. The FIQ was
developed by Burkhardt et al. to evaluate the health
condition of the FMs patients. This scale includes 10
items. The first item concerns with the daily activities
and is composed of Likert type 10 questions each
scored between 0-3. In the second and third items the
impact level by disease and the number of days that the
patient couldn’t go work were recorded. The
remaining 7 questions assess difficulty in performing
work, pain, fatigue, morning stiffness, anxiety and
depression. The highest score is 100 and indicates the
worst functional condition.
In laboratory evaluations, the total blood count,
erythrocyte sedimentation rate (ESR) (standard
Westergren method), C-reactive protein (CRP) level
(nephelometry), routine biochemical tests and thyroid
function tests were recorded. Those with any systemic
disease (diabetes mellitus, hypertension, liver-kidney
function disorders, thyroid function disorders,
anemia, active infection, inflammatory rheumatic
disease) were excluded from the study.
The serum and urine magnesium levels were
measured by original kits of Abbott Aeroset
autoanaylzer (Abbott Laboratories, Abbott Park, IL,
60064, USA). The principle of the study is based on
measuring the absorbance of the magnesium-
Arsenazo stain complex at 572 nm. Absorbance and
the magnesium concentration are proportional to each
other. The intraassay CV% of the measurement is
2.6% for serum whereas the interassay CV% is 0.6%.
For urine, these values are 3.8% and 0.0%,
respectively. The normal range of serum magnesium
is 1.6-2.6 mg/dl and the normal range of 24hour urine
magnesium level is 6-10 m Eq/l.
Oral magnesium citrate (Magnesium-Diasporal
sachets b.i.d) 600 mg/day was administered to the
patients for two months. The patients were not allowed
to take any analgesic drugs during treatment. The day
and night pain, sensitive point count, functional
capacity, serum and 24-hours urine magnesium levels
recorded pre-treatment and two months post-
treatment were compared.
The software package for Social Sciences
(SPSS) 11.0 was used for the purpose of statistical
analysis. Descriptive values were presented in
numbers and percentages via mediums and standard
deviations. The comparison of the pre-and post-
treatment clinical findings was performed by
Wilcoxon signed ranks test.
The mean (SD) age of the patients was found to
be as 44.8 (7.4) years, the mean duration of the disease
25.4 (19.3) months, and Body Mass Index (BMI) 26.3
(4). The socio-demographical data of the patients were
given in table 1. As shown in table 2, the most
frequently encountered symptoms accompanying
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Age [year, mean (SD)] 44.8(7.4)
Table 1: Some of the clinical characteristics of
fibromyalgia patients
F/M: Female/Male
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FMs patients were arthralgia, myalgia, anxiety,
forgetfulness, sleep disturbance and fatigue. Clinical
and laboratory findings in patients with FMs pre- and
post- oral magnesium therapy were given in table 3.
Statistically significant (p<0.001) decreases were
found at the post-treatment 2nd month in terms of day
and night pain, sensitive point count and FIQ score
when compared to the pre-treatment period. No
statistically significant changes were detected in
serum and 24-hours urine magnesium levels at the end
of the 2nd month compared to the pre-treatment period
(p>0.05). No adverse effects were observed in patients
due to the medication.
In our study, significant improvements were
achieved in clinical pain, sensitive point count and
functional capacity of the FMS patients by
administration of oral magnesium citrate for the
duration of two months. Some evidence exists
supporting the possibility of deficiency of components
required for ATP synthesis in etio-pathogenesis of
FMs. Oxygen, magnesium, substrate, ADP and
phosphate are required for ATP synthesis. In case each
of these is in optimal concentrations, a healthy
mitochondrial respiration and a concurrent biological
energy production can occur. On the other hand, their
deficiencies result in decelerating of crebs cycle,
increase of anaerobic glycolysis, increase in lactic acid
formation, and decrease of the maximum lung
capacity. The combination of these factors may cause
fatigue, depression and muscle pain symptoms. Some
evidence exist supporting the fact that magnesium is
one of the most critical elements forATP synthesis and
may be below normal limits in FMs patients. The
mitochondrial uptake and accumulation of
magnesium is directly associated to uptake of the
required phosphate for ADP phosphorilation.
Therefore, the completion of the crebs cycle is a
magnesium-dependent mechanism and even a mild
deficiency of magnesium can impair the optimal
function. The associated problems due to magnesium
deficiency include mitochondrial swelling, increase in
the membrane permeability, decrease in the selectivity
of the mitochondrial inner membrane, uncoupling of
oxidative phosphorilation and a possible aluminum
toxicity. Similar mitochondrial anomalies were
reported from the muscle biopsies obtained from
painful points of FMs patients.
The most frequently observed symptoms in FMs
are myalgia , chronic fatigue syndrome , irritable
bowel syndrome , mitral valve prolapsus , stress-
dependent headache and dysmenorrhea . Several
symptoms similar to those of FMs were reported to
occur also in magnesium deficiency. Moreover,
Abraham et al claimed that a possible mechanism
responsible for pain in FMs patients is the magnesium
deficiency. However, a few of studies were present
investigating the magnesium deficiency in the patients
with FMs. In these studies, it was also reported that
the serum magnesium level was not changed.
Consistent with all these studies, the pre-treatment and
second month post-treatment serum and 24-hours
urine magnesium levels of the patients in our study
were within normal ranges and the levels did not
undergo any significant changes. Magaldi et al
reported that the plasmatic magnesium level was
normal in FMs patients and the intracellular
magnesium level was responsible from the
pathophysiology of the disease. In the similar studies,
Eisinger et al reported that they found the
erythrocyte magnesium levels were markedly low in
FMs. Therefore, the magnesium levels in blood cells
or sublingual cells provide more accurate results.
However, it would be difficult to interpret the results of
our study since we couldn’t able to measure the
intracellular magnesium level technically.
The most frequently observed additional
symptom in our patients was fatigue (100%). Fatigue
is among the most frequent symptoms in FMs patients.
The patients generally feel fatigue all day long and its
severity is at significance levels. Magnesium plays
an important role in enzymatic reactions that
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SIGNS AND
SYMPTOMS
FREQUENCY (%)
Myalgia 96
Fatigue 100
Sleep disorders 76
Concentration
disturbance
48
Forgetfulness 80
Irritable bowel syndrome 60
Irritable bladder
syndrome
48
Raynaud phenomena 20
Legs cramp 60
Anxiety 96
Table 2: Common signs and symptoms of our patients
with fibromyalgia
Table 3: Clinical and laboratory findings in patients with fibromyalgia pre- and post- trace element therapy
Pretreatment
Mean(SD)
Post-treatment
Mean (SD) P*
especially function in energy production. As the
magnesium levels decline the energy levels also
decline and consequently fatigue may occur.
Magnesium supplementation may benefit in the
treatment of chronic fatigue.
We did not encounter any studies in the literature
that research the efficacy of magnesium therapy
individually in FMs patients. However, Abraham et
al studied the efficacy of the combined oral
magnesium and malic acid therapy in 15 FMs patients.
They administered both 1200-2400 mg/day malic acid
and 300-600 mg/day magnesium to patients for 4-8
weeks.As a consequence of the study they found that a
significant pain relief was gained at 48 hours of the
treatment and statistically significant decrease in
sensitive point count in 4-8 weeks in all the patients.At
the end of 8 weeks only 6 patients underwent a placebo
therapy for two weeks and a statistically significant
increase was observed in sensitive point count. In our
study, we also detected a marked decline in day pain,
night pain and sensitive point count following the 600
mg/day oral magnesium therapy (p<0.001). In another
study , magnesium, massage therapy, vitamin
supplement and a weight reduction program were
applied to FMs patients and this combined treatment
seemed to be useful. Holdcraft et al also reported that
acupuncture, massage therapy and some nutritional
support accompanying magnesium treatment to be
effective in FMs patients. Similarly, Sarac et al
emphasized that magnesium supplement, massage
therapy and nutritional support to be effective on the
disease.
We administered FIQ for the functional
assessment of our patients. FIQ is a scale which is able
to asses the most frequently complained symptoms by
FMs patients such as physical work, depression,
anxiety, sleep, pain, stiffness, fatigue and
uncomfortable feeling. In our study, a statistically
significant improvement was observed in FIQ score at
the end of two month therapy (p<0.001). Since we
didn’t come across such a study concerning this topic,
according to our data we may suggest that the
pronounced improvement in FIQ indicates the real
efficacy of the treatment.
In conclusion, administration of oral magnesium
citrate 600 mg/day was found to be effective and safe
on sensitive point count, pain and functional capacity
in FMs treatment. Therefore, oral magnesium therapy
may be advised to FMs patients. We suggest that this
inference should be supported by placebo controlled
studies.
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